Cargando…

C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study

BACKGROUND: Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first‐line treatment for advanced non‐small cell lung cancer (NSCLC). However, the therapeutic effect of combination immunotherapy has not been fully investigated. C‐reactive protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonehara, Kei, Ozawa, Ryota, Hama, Mineyuki, Nozawa, Shuhei, Agatsuma, Toshihiko, Nishie, Kenichi, Kato, Akane, Matsuo, Akemi, Araki, Taisuke, Komatsu, Masamichi, Tateishi, Kazunari, Hanaoka, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968595/
https://www.ncbi.nlm.nih.gov/pubmed/36635979
http://dx.doi.org/10.1111/1759-7714.14798
_version_ 1784897531900067840
author Sonehara, Kei
Ozawa, Ryota
Hama, Mineyuki
Nozawa, Shuhei
Agatsuma, Toshihiko
Nishie, Kenichi
Kato, Akane
Matsuo, Akemi
Araki, Taisuke
Komatsu, Masamichi
Tateishi, Kazunari
Hanaoka, Masayuki
author_facet Sonehara, Kei
Ozawa, Ryota
Hama, Mineyuki
Nozawa, Shuhei
Agatsuma, Toshihiko
Nishie, Kenichi
Kato, Akane
Matsuo, Akemi
Araki, Taisuke
Komatsu, Masamichi
Tateishi, Kazunari
Hanaoka, Masayuki
author_sort Sonehara, Kei
collection PubMed
description BACKGROUND: Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first‐line treatment for advanced non‐small cell lung cancer (NSCLC). However, the therapeutic effect of combination immunotherapy has not been fully investigated. C‐reactive protein, performance status, lactate dehydrogenase, albumin, and derived neutrophil‐to‐lymphocyte ratio (C‐PLAN) are useful biomarkers for predicting the prognosis of NSCLC; however, there are no reports examining the C‐PLAN index, which combines these five factors in a single prognostic factor. METHODS: We retrospectively collected data from 178 patients with previously untreated advanced NSCLC who received combination immunotherapy at multicenter institutions in Nagano Prefecture between December 2018 and April 2022. We investigated the utility of the C‐PLAN index as a prognostic factor using Cox regression analysis and correlated it with survival. RESULTS: The good and poor C‐PLAN index groups included 85 and 93 patients, respectively. The good C‐PLAN index group had a longer median progression‐free survival (PFS) (10.7 vs. 6.0 months; p = 0.022) and overall survival (OS) (25.3 vs. 16.5 months; p = 0.003) than the poor C‐PLAN index group. The C‐PLAN index was an independent favorable prognostic factor that correlated with PFS and OS in multivariate analysis. The good C‐PLAN index group had a higher proportion of never‐smokers (16.5 vs. 4.3%; p = 0.007) and stage III disease/postoperative recurrence (32.9 vs. 15.1%; p = 0.005) than the poor C‐PLAN index group. CONCLUSION: The C‐PLAN index is a useful prognostic factor for patients with previously untreated advanced NSCLC undergoing combination immunotherapy.
format Online
Article
Text
id pubmed-9968595
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-99685952023-02-28 C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study Sonehara, Kei Ozawa, Ryota Hama, Mineyuki Nozawa, Shuhei Agatsuma, Toshihiko Nishie, Kenichi Kato, Akane Matsuo, Akemi Araki, Taisuke Komatsu, Masamichi Tateishi, Kazunari Hanaoka, Masayuki Thorac Cancer Original Articles BACKGROUND: Combination immunotherapy (immune checkpoint inhibitors and cytotoxic anticancer agents) is widely used as first‐line treatment for advanced non‐small cell lung cancer (NSCLC). However, the therapeutic effect of combination immunotherapy has not been fully investigated. C‐reactive protein, performance status, lactate dehydrogenase, albumin, and derived neutrophil‐to‐lymphocyte ratio (C‐PLAN) are useful biomarkers for predicting the prognosis of NSCLC; however, there are no reports examining the C‐PLAN index, which combines these five factors in a single prognostic factor. METHODS: We retrospectively collected data from 178 patients with previously untreated advanced NSCLC who received combination immunotherapy at multicenter institutions in Nagano Prefecture between December 2018 and April 2022. We investigated the utility of the C‐PLAN index as a prognostic factor using Cox regression analysis and correlated it with survival. RESULTS: The good and poor C‐PLAN index groups included 85 and 93 patients, respectively. The good C‐PLAN index group had a longer median progression‐free survival (PFS) (10.7 vs. 6.0 months; p = 0.022) and overall survival (OS) (25.3 vs. 16.5 months; p = 0.003) than the poor C‐PLAN index group. The C‐PLAN index was an independent favorable prognostic factor that correlated with PFS and OS in multivariate analysis. The good C‐PLAN index group had a higher proportion of never‐smokers (16.5 vs. 4.3%; p = 0.007) and stage III disease/postoperative recurrence (32.9 vs. 15.1%; p = 0.005) than the poor C‐PLAN index group. CONCLUSION: The C‐PLAN index is a useful prognostic factor for patients with previously untreated advanced NSCLC undergoing combination immunotherapy. John Wiley & Sons Australia, Ltd 2023-01-12 /pmc/articles/PMC9968595/ /pubmed/36635979 http://dx.doi.org/10.1111/1759-7714.14798 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Sonehara, Kei
Ozawa, Ryota
Hama, Mineyuki
Nozawa, Shuhei
Agatsuma, Toshihiko
Nishie, Kenichi
Kato, Akane
Matsuo, Akemi
Araki, Taisuke
Komatsu, Masamichi
Tateishi, Kazunari
Hanaoka, Masayuki
C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
title C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
title_full C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
title_fullStr C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
title_full_unstemmed C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
title_short C‐PLAN index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: A multicenter retrospective study
title_sort c‐plan index as a prognostic factor for patients with previously untreated advanced non‐small cell lung cancer who received combination immunotherapy: a multicenter retrospective study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968595/
https://www.ncbi.nlm.nih.gov/pubmed/36635979
http://dx.doi.org/10.1111/1759-7714.14798
work_keys_str_mv AT soneharakei cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT ozawaryota cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT hamamineyuki cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT nozawashuhei cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT agatsumatoshihiko cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT nishiekenichi cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT katoakane cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT matsuoakemi cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT arakitaisuke cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT komatsumasamichi cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT tateishikazunari cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy
AT hanaokamasayuki cplanindexasaprognosticfactorforpatientswithpreviouslyuntreatedadvancednonsmallcelllungcancerwhoreceivedcombinationimmunotherapyamulticenterretrospectivestudy